Universal azole prophylaxis for prevention of coccidioidomycosis among lung transplant recipients transferring care to a center within a highly endemic region
Transplant Infectious Disease · 2025
DOI: 10.1111/tid.14379 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Kellie J Goodlet und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Midwestern University College of Pharmacy, Glendale, Arizona, USA. Hauptthemen laut MEDLINE: Coccidioidomycosis, Lung Transplantation, Antifungal Agents, Transplant Recipients. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Background
Coccidioidomycosis may cause severe disseminated disease and mortality among lung transplant recipients. A strategy of lifelong azole prophylaxis was previously associated with low rates of coccidioidomycosis. Whether lung transplant recipients relocating to the Coccidioides endemic region are also at risk and would benefit from antifungal prophylaxis is unknown.
Methods
Lung transplant recipients transplanted at an outside center with low Coccidioides endemicity before relocating for post‐transplant follow‐up at a transplant center in Phoenix, Arizona from January 2013 to March 2024 were included. The primary outcome was proven or probable coccidioidomycosis per Mycoses Study Group consensus definitions.
Results
Forty lung transplant recipients were included, with 62.5% not receiving antifungal prophylaxis at the time of transfer. The median time from transplant to relocation was 34 months. Of those not on prophylaxis, 96% were initiated on azole therapy at the first clinic visit, with 72% prescribed itraconazole. Coccidioides serologic testing was performed in 30% of the cohort, most often in the context of a broad diagnostic work‐up for suspected infection during hospitalization. After a median follow‐up of 31 months, one case (2.5%) of proven pulmonary coccidioidomycosis was identified, occurring 4.8 years post‐transplant and >2 years post‐transfer in a cystic fibrosis patient who had a pause in fluconazole prophylaxis for >1 month prior to diagnosis due to gastrointestinal intolerance and access issues. The patient was treated and maintained on isavuconazole without complications.
Conclusion
Azole antifungal prophylaxis was associated with a low rate of coccidioidomycosis among lung transplant recipients relocating to the highly endemic region. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, Midwestern University College of Pharmacy, Glendale, Arizona, USA.
- Department of Pharmacy Services, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
- Division of Transplant Pulmonology, Norton Thoracic Institute, Dignity Health, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
ORCID-Profile: Kellie J Goodlet
Zitieren
APA
Goodlet, K. J., Garcia, R., & Nailor, M. D. (2025). Universal azole prophylaxis for prevention of coccidioidomycosis among lung transplant recipients transferring care to a center within a highly endemic region. Transplant Infectious Disease. https://doi.org/10.1111/tid.14379
Vancouver
Goodlet KJ, Garcia R, Nailor MD. Universal azole prophylaxis for prevention of coccidioidomycosis among lung transplant recipients transferring care to a center within a highly endemic region. Transplant Infectious Disease. 2025. doi:10.1111/tid.14379
BibTeX
@article{Goodlet2025,
author = {Goodlet, Kellie J and Garcia, Rhiannon and Nailor, Michael D},
title = {Universal azole prophylaxis for prevention of coccidioidomycosis among lung transplant recipients transferring care to a center within a highly endemic region},
journal = {Transplant Infectious Disease},
year = {2025},
doi = {10.1111/tid.14379}
}
EUVIMED